Logo image of ABUS

ARBUTUS BIOPHARMA CORP (ABUS) Stock Fundamental Analysis

NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD

3.42  -0.02 (-0.58%)

After market: 3.4 -0.02 (-0.58%)

Fundamental Rating

3

ABUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ABUS as it has an excellent financial health rating, but there are worries on the profitability. ABUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABUS has reported negative net income.
ABUS had a negative operating cash flow in the past year.
ABUS had negative earnings in each of the past 5 years.
In the past 5 years ABUS always reported negative operating cash flow.
ABUS Yearly Net Income VS EBIT VS OCF VS FCFABUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

ABUS has a Return On Assets of -54.61%. This is comparable to the rest of the industry: ABUS outperforms 44.74% of its industry peers.
ABUS has a Return On Equity (-71.76%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.61%
ROE -71.76%
ROIC N/A
ROA(3y)-43.07%
ROA(5y)-68.17%
ROE(3y)-57.21%
ROE(5y)-94.56%
ROIC(3y)N/A
ROIC(5y)N/A
ABUS Yearly ROA, ROE, ROICABUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

ABUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABUS Yearly Profit, Operating, Gross MarginsABUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABUS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABUS has been increased compared to 5 years ago.
There is no outstanding debt for ABUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABUS Yearly Shares OutstandingABUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ABUS Yearly Total Debt VS Total AssetsABUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ABUS has an Altman-Z score of -2.56. This is a bad value and indicates that ABUS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.56, ABUS perfoms like the industry average, outperforming 49.91% of the companies in the same industry.
ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.56
ROIC/WACCN/A
WACC9.51%
ABUS Yearly LT Debt VS Equity VS FCFABUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 7.02 indicates that ABUS has no problem at all paying its short term obligations.
ABUS has a better Current ratio (7.02) than 67.02% of its industry peers.
A Quick Ratio of 7.02 indicates that ABUS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.02, ABUS is doing good in the industry, outperforming 67.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.02
Quick Ratio 7.02
ABUS Yearly Current Assets VS Current LiabilitesABUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

ABUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.88%, which is quite good.
ABUS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -69.70%.
The Revenue has been growing by 24.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-69.7%
Revenue growth 3Y37.95%
Revenue growth 5Y24.98%
Sales Q2Q%-71.25%

3.2 Future

The Earnings Per Share is expected to grow by 7.96% on average over the next years.
Based on estimates for the next years, ABUS will show a very strong growth in Revenue. The Revenue will grow by 22.20% on average per year.
EPS Next Y10.05%
EPS Next 2Y11.4%
EPS Next 3Y1.62%
EPS Next 5Y7.96%
Revenue Next Year-70.27%
Revenue Next 2Y-50.01%
Revenue Next 3Y-26.03%
Revenue Next 5Y22.2%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ABUS Yearly Revenue VS EstimatesABUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ABUS Yearly EPS VS EstimatesABUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABUS Price Earnings VS Forward Price EarningsABUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABUS Per share dataABUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.4%
EPS Next 3Y1.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (2/21/2025, 8:00:00 PM)

After market: 3.4 -0.02 (-0.58%)

3.42

-0.02 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners55.36%
Inst Owner Change-98.62%
Ins Owners0.95%
Ins Owner Change0.68%
Market Cap648.06M
Analysts81.82
Price Target5.3 (54.97%)
Short Float %4.56%
Short Ratio8.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.34%
Min EPS beat(2)-11.41%
Max EPS beat(2)6.73%
EPS beat(4)3
Avg EPS beat(4)1.62%
Min EPS beat(4)-11.41%
Max EPS beat(4)10.87%
EPS beat(8)5
Avg EPS beat(8)5.07%
EPS beat(12)9
Avg EPS beat(12)10.5%
EPS beat(16)11
Avg EPS beat(16)8.46%
Revenue beat(2)0
Avg Revenue beat(2)-16.51%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-3.58%
Revenue beat(4)0
Avg Revenue beat(4)-33.46%
Min Revenue beat(4)-56.13%
Max Revenue beat(4)-3.58%
Revenue beat(8)1
Avg Revenue beat(8)-19.51%
Revenue beat(12)4
Avg Revenue beat(12)8.69%
Revenue beat(16)7
Avg Revenue beat(16)8.22%
PT rev (1m)0%
PT rev (3m)4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.08%
EPS NY rev (1m)0%
EPS NY rev (3m)0.87%
Revenue NQ rev (1m)-1.24%
Revenue NQ rev (3m)-5.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.12
P/FCF N/A
P/OCF N/A
P/B 6.06
P/tB 6.06
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.04
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.61%
ROE -71.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.07%
ROA(5y)-68.17%
ROE(3y)-57.21%
ROE(5y)-94.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.71%
Cap/Sales 1.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.02
Quick Ratio 7.02
Altman-Z -2.56
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)51.25%
Cap/Depr(5y)38.89%
Cap/Sales(3y)4.74%
Cap/Sales(5y)5.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y10.05%
EPS Next 2Y11.4%
EPS Next 3Y1.62%
EPS Next 5Y7.96%
Revenue 1Y (TTM)-69.7%
Revenue growth 3Y37.95%
Revenue growth 5Y24.98%
Sales Q2Q%-71.25%
Revenue Next Year-70.27%
Revenue Next 2Y-50.01%
Revenue Next 3Y-26.03%
Revenue Next 5Y22.2%
EBIT growth 1Y0.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.18%
OCF growth 3YN/A
OCF growth 5YN/A